e.l.f. Beauty, Inc. ELF 深 滬
等待開盤 07-18 09:30:00 美东时间
110.90
+2.390
+2.20%
華盛通- 最 高111.80
- 今 開108.20
- 成交量 176.65万股
- 最 低 108.03
- 昨 收 108.51
- 總市值 62.47亿
- 52周最高 190.38
- 市盈率 靜 57.73
- 換手率 3.14%
- 52周最低 49.40
- 委 比 -20.00%
- 總股本 5632.84万
- 歷史最高 221.8299
- 量 比 0.87
- 振 幅 3.47%
- 歷史最低 6.705
- 每 手 1
- 風險率 33.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Assessing e.l.f. Beauty: Insights From 22 Financial Analysts
22 analysts have expressed a variety of opinions on e.l.f. Beauty (NYSE:ELF) ov...
07-17 22:02
UBS Maintains Neutral on e.l.f. Beauty, Raises Price Target to $120
UBS analyst Peter Grom maintains e.l.f. Beauty (NYSE:ELF) with a Neutral and raises the price target from $95 to $120.
07-17 21:17
Analysts Offer Insights on Consumer Cyclical Companies: e.l.f. Beauty (ELF) and Gambling.com (GAMB)
There’s a lot to be optimistic about in the Consumer Cyclical sector as 2 analy...
07-16 18:51
美股大行评级 | 潜在涨幅107.37%！花旗上调ProKidney目标价至9美元，维持"买入"评级
今日重点评级关注：花旗：维持ProKidney Corp. - Class A Ordinary Shares"买入"评级，目标价从6美元升至9美元；Canaccord Genuity：维持e.l.f. Beauty"买入"评级，目标价从114美元升至150美元
07-10 09:55
Canaccord Genuity Maintains Buy on e.l.f. Beauty, Raises Price Target to $150
Canaccord Genuity analyst Susan Anderson maintains e.l.f. Beauty (NYSE:ELF) with a Buy and raises the price target from $114 to $150.
07-10 00:21
Altimmune Enrols First Patient In RESTORE Phase 2 Trial Evaluating Efficacy And Safety Of Pemvidutide In Subjects With Alcohol-Associated Liver Disease
Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first patient in
07-09 19:31
Altimmune Announces Topline Results From IMPACT Phase 2b Trial Of Pemvidutide In MASH; Trial Meets "Primary Endpoint With Statistically Significant MASH Resolution Without Worsening Of Fibrosis In Up To 59.1% Of Participants In ITT Analysis"
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeksTrial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of
06-26 19:09
首发、首秀、首演纷纷“落地”—— “首”选南京，这座城做对了什么？
6月25日，2025首发经济发展大会展示区，中航金城集团展出JC-M15多旋翼无人机。 南京日报/紫金山新闻记者 戚珂嘉 摄 □南京日报/紫金山新...
06-26 06:54
美股大行评级 | 潜在涨幅378.93%！aTyr Pharma获富国银行升目标价至25美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1143101010774646784.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 富国银行：维持aTyr Pharma(ATYR)"超配"评级，目标价从17美元升至25美元</p> <p>• 摩根大通：维持Array Technologies(ARRY)"超配"评级，目标价从12美元升至13美元</p>
06-21 08:35
B of A Securities Maintains Buy on e.l.f. Beauty, Raises Price Target to $135
B of A Securities analyst Anna Lizzul maintains e.l.f. Beauty (NYSE:ELF) with a Buy and raises the price target from $113 to $135.
06-21 01:05
